Tumor Biology

, Volume 37, Issue 4, pp 4955–4961 | Cite as

Predictive value of blood lipid association with response to neoadjuvant chemoradiotherapy in colorectal cancer

  • Yan Wang
  • Chengxin Liu
  • Jianbo Zhang
  • Yuanyuan Liu
  • Guanzhong Gong
  • Xinkai Mo
  • Pei Liu
  • Baosheng Li
  • Yong Yin
Original Article


The aim of this research was to explore whether blood lipid parameters could predict tumor regression grading (TRG) and compare with the predictive value of carcinoembryonic antigen (CEA) in patients with locally advanced colorectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT). Between June 2011 and January 2015, the records of 176 patients with primary colorectal adenocarcinoma treated with nCRT followed by radical surgery were reviewed retrospectively. Total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and pre-CEA were measured before nCRT, and post-CEA was measured before surgery. A total of 129 (73.3 %) good responders (TRG 3–4) and 47 (26.7 %) poor responders (TRG 0–2) were assessed after the nCRT. TC, LDL, HDL, and ΔCEA were 6.56 ± 0.95, 3.08 ± 0.72, and 1.43 ± 0.25 mmol/L and −0.69 ± 8.33 μg/mL in poor responders compared with 5.15 ± 1.29, 2.39 ± 0.5, and 1.37 ± 0.32 mmol/L and 16.67 ± 30.18 μg/mL in good responders, respectively (p < 0.05). TG, pre-CEA, and post-CEA were not significantly different. Multivariate logistic regression analysis revealed TC and ΔCEA as independent factors in predicting TRG; TC showed a sensitivity of 62.79 %, a specificity of 91.49 %, a Youden index of 0.543, a cutoff value of 5.52, and an AUC of 0.800 compared with ΔCEA (sensitivity 76.74 %, specificity 65.96 %, Youden index 0.427, and AUC 0.761). TC has a better predictive value than ΔCEA and hence might serve as a predictor of TRG in LARC patients.


Blood lipid parameters Neoadjuvant chemoradiotherapy Prediction Colorectal cancer Tumor regression grading 



The National Natural Science Fund of Shandong Province (No. ZR2015PH012 and No. ZR2015YL031) and Research Award Fund for Outstanding Young Scientists of Shandong Province (No. BS2011YY016) aided this research. The assistance from the clinical and technical colleagues is highly appreciated, who provided immense support during protocol designing, data collection and analysis, and manuscript writing.

Compliance with ethical standards

Conflicts of interest


Ethics approval and consent to participate

The study was approved by the Institutional Review Board. Informed consent was obtained from each patient.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Benson 3rd AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, et al. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:449–54.PubMedGoogle Scholar
  3. 3.
    Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer: a 2006 update. World J Gastroenterol. 2006;12:3186–95.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829–38.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Molinari C, Matteucci F, Caroli P, Passardi A. Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2015;05:14.Google Scholar
  6. 6.
    Kim CH, Lee SY, Kim HR, Kim YJ. Prognostic effect of pretreatment serum carcinoembryonic antigen level: a useful tool for prediction of distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and total mesorectal excision. Medicine (Baltimore). 2015;94:31.Google Scholar
  7. 7.
    van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011;60:1094–102.CrossRefPubMedGoogle Scholar
  8. 8.
    Kitahara CM, Berrington de González A, Freedman ND, Huxley R, Mok Y, Jee SH, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29:1592–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulationof the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010;107:15051–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Brañes J, et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2010;14:1180–93.PubMedGoogle Scholar
  11. 11.
    Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, Ogaki M, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res. 2010;29:127.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh Choudhury G. Simvastatin induces derepression of PTEN expression via NF kappaB to inhibit breast cancer cell growth. Cell Signal. 2010;22:749–58.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    He YS, Jin HY, Zhang JC, Zhou AC. [Experimental study of the impact of hyperlipidemia on the chemotherapy in colorectal cancer model]. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:583–7.PubMedGoogle Scholar
  14. 14.
    Butt S, Butt T, Jirström K, Hartman L, et al. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Ann Surg Oncol. 2014;21:2911–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Solanki AA, Liauw SL. Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access J Urol. 2011;3:95–104.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19–23.CrossRefPubMedGoogle Scholar
  18. 18.
    Huh JW, Park YA, Jung EJ, Lee KY, Sohn SK. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. J Am Coll Surg. 2008;207:7–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Konski A, Li T, Sigurdson E, Cohen SJ, Small Jr W, Spies S, et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009;74:55–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Kremser C, Trieb T, Rudisch A, Judmaier W, de Vries A. Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: sequence implementation and data analysis. J Magn Reson Imaging. 2007;26:662–71.CrossRefPubMedGoogle Scholar
  21. 21.
    Kim JW, Kim HC, Park JW, Park SC, Sohn DK, Choi HS, et al. Predictive value of 18FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy. Int J Colorectal Dis. 2013;28:1217–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Hur H, Kim NK, Min BS, Baik SH, Lee KY, Koom WS, et al. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer? Dis Colon Rectum. 2014;57:592–601.CrossRefPubMedGoogle Scholar
  23. 23.
    Moreno García V, Cejas P, Blanco Codesido M, Feliu Batlle J, de Castro Carpeño J, Belda-Iniesta C, et al. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2009;24:741–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, et al. Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis. Cancer Sci. 2014;105:818–24.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yang KL, Yang SH, Liang WY, et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013;8:43.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kim CW, Yu CS, Yang SS, et al. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2011;18:3271–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Li C, Wang Z, Liu F, Zhu J, Yang L, Cai G, et al. CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumour Biol. 2014;35:9683–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Kopecka J, Campia I, Olivero P, et al. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release. 2011;149:196–205.CrossRefPubMedGoogle Scholar
  29. 29.
    Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006;168:1107e1118.Google Scholar
  30. 30.
    Riganti C, Castella B, Kopecka J, et al. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One. 2013;8:e60975.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Zhang Y, Duan G, Feng S. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun. 2015;459:367–73.CrossRefPubMedGoogle Scholar
  32. 32.
    Connelly-Smith L, Pattinson J, Grundy M, et al. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Exp Hematol. 2007;35:1793–800.CrossRefPubMedGoogle Scholar
  33. 33.
    Gelsomino G, Corsetto PA, Campia I, et al. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer. 2013;12:137.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Eckford PD, Sharom FJ. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry. 2008;47:13686–98.CrossRefPubMedGoogle Scholar
  35. 35.
    Babcook MA, Shukla S, Fu P, et al. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2014;13:2288–302.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm. 2011;8:683–700.CrossRefPubMedGoogle Scholar
  37. 37.
    Hamm R, Zeino M, Frewert S, et al. Up-regulation of cholesterol associated genes as novel resistance mechanism in glioblastoma cells in response to archazolid B. Toxicol Appl Pharmacol. 2014;281(1):78–86.CrossRefPubMedGoogle Scholar
  38. 38.
    Hamm R, Chen YR, Seo EJ, et al. Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells. Biochem Pharmacol. 2014;91:18–30.CrossRefPubMedGoogle Scholar
  39. 39.
    Steinberg D. The statins in preventive cardiology. N Engl J Med. 2008;359:1426–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Meyer dos Santos S, Weber CC, Franke C, et al. Cholesterol: coupling between membrane microenvironment and ABC transporter activity. Biochem Biophys Res Commun. 2007;354:216–21.CrossRefPubMedGoogle Scholar
  41. 41.
    Souchek JJ, Baine MJ, Lin C, et al. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Br J Cancer. 2014;111:1139–49.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bionda C, Athias A, Poncet D, et al. Differential regulation of cell death in head and neck cell carcinoma through alteration of cholesterol levels in lipid rafts microdomains. Biochem Pharmacol. 2008;75:761–72.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yan Wang
    • 1
  • Chengxin Liu
    • 2
  • Jianbo Zhang
    • 2
  • Yuanyuan Liu
    • 3
  • Guanzhong Gong
    • 2
  • Xinkai Mo
    • 2
  • Pei Liu
    • 4
  • Baosheng Li
    • 2
  • Yong Yin
    • 2
  1. 1.Department of Radiation Oncology, Qilu HospitalShandong UniversityJinanChina
  2. 2.Department of Radiation OncologyShandong Cancer Hospital and InstituteJinanChina
  3. 3.Department of Medical Record StatisticsShandong Jiaotong HospitalJinanChina
  4. 4.Department of Plastic Surgery, Qilu HospitalShandong UniversityJinanChina

Personalised recommendations